Avacopan

Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.[1][3] Avacopan was approved for medical use in Japan in September 2021,[2] and in the United States in October 2021.[1][3] It is the first orally-administered inhibitor of the complement C5a receptor approved by the U.S. Food and Drug Administration (FDA).[3] C... [wikipedia]